Literature DB >> 24988615

Mitigating the effects of churning under the Affordable Care Act: lessons from Medicaid.

Sara Rosenbaum1, Nancy Lopez, Mark Dorley, Joel Teitelbaum, Taylor Burke, Jacqueline Miller.   

Abstract

Through a combination of three needs-based public programs--Medicaid, the Children's Health Insurance Program, and tax credits for purchasing private plans in the new marketplaces--the Affordable Care Act can potentially ensure continuous coverage for many low- and moderate-income Americans. At the same time, half of individuals with incomes at less than twice the poverty level will experience a form of "churning" in their coverage; as changes occur in their life or work circumstances, they will need to switch among these three coverage sources. For many, churning will entail not only changes in covered benefits and cost-sharing, but also in care, owing to differences in provider networks. Strategies for mitigating churning's effects are complex and require time to implement. For the short term, however, the experiences of 17 states with policies aimed at smoothing transitions between health plans offer lessons for ensuring care continuity.

Entities:  

Mesh:

Year:  2014        PMID: 24988615

Source DB:  PubMed          Journal:  Issue Brief (Commonw Fund)        ISSN: 1558-6847


  3 in total

1.  Does Churning in Medicaid Affect Health Care Use?

Authors:  Eric T Roberts; Craig Evan Pollack
Journal:  Med Care       Date:  2016-05       Impact factor: 2.983

Review 2.  Key Provisions of the Patient Protection and Affordable Care Act (ACA): A Systematic Review and Presentation of Early Research Findings.

Authors:  Michael T French; Jenny Homer; Gulcin Gumus; Lucas Hickling
Journal:  Health Serv Res       Date:  2016-06-05       Impact factor: 3.402

3.  Medicaid Work Requirements In Arkansas: Two-Year Impacts On Coverage, Employment, And Affordability Of Care.

Authors:  Benjamin D Sommers; Lucy Chen; Robert J Blendon; E John Orav; Arnold M Epstein
Journal:  Health Aff (Millwood)       Date:  2020-09       Impact factor: 6.301

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.